NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago. These figures ...

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of ...

NeoGenomics Inc. (NEO) on Tuesday reported a loss of $9.9 million in its fourth quarter. The Fort Myers, Florida-based company said it had a loss of ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q4 CY2025 results , with sales up 10.6% year on year ...

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a ...

NeoGenomics has seen a strong start to the year. The Fort Myers-based cancer testing and research lab reported revenue growth of 8% in the first quarter over the year. Revenue rose from roughly $156.2 ...

New integrated testing approach provides potential to deliver earlier biomarker insights, reduce diagnostic uncertainty in complex cancer cases, and enable confident clinical decisionsFORT MYERS, Fla.

NeoGenomics (NASDAQ:NEO) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement. Analysts estimate that NeoGenomics will ...

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, ...

NeoGenomics NEO has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ...